Composite Bone Void Filler

The bone void filler has been cleared by the U.S. Food and Drug Administration (FDA).

The filler is called Polygraft TCP bone graft substitute. The porous material is composed of a patented blend of polylactide-co-glycolide, tricalcium phosphate, and polyglycolide fibers. It is intended to be gently packed into bony voids or gaps of the extremities, spine, or pelvis, and these defects may be surgically created osseous defects or bone defects due to traumatic injury to the bone. Polygraft TCP was developed by OsteoBiologics, Inc. (OBI, San Antonio, TX, USA; www.obi.com). The company is focusing on commercializing and further developing its platform technologies in arthroscopy and sports medicine.

"OBI has developed another composite bone void filler in which the ceramic portion resorbs slower to enhance strength retention,” said Fred Dinger, president and CEO of OBI. "The availability of this technology platform gives OBI the opportunity to continue our rapid product line expansion and enables us to provide solutions for the body to heal itself for a broader range of unmet clinical needs.”




Related Links:
OBI